Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients

Launched by TANTA UNIVERSITY · Mar 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called Aflibercept, delivered through an injection in the eye, for patients with certain eye conditions related to diabetes, such as diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization. These conditions can lead to vision problems and are often difficult to treat. The trial aims to find out if this higher dose of Aflibercept can help patients who haven't responded to other treatments.

To qualify for this study, participants should have resistant DME, which means their condition hasn't improved with previous treatments. However, individuals with certain eye problems or those who have had recent eye surgeries won't be able to participate. The trial is not yet recruiting participants, but once it starts, those who are eligible can expect to receive the treatment and be monitored for how well it works in improving their vision. This trial is important because it may offer new hope for patients struggling with these eye conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • This study included resistant centrally involved diabetic macular edema (DME) cases
• • -
• Exclusion Criteria:
• • 1. Patients with a history of intraocular surgery
• • 2. coincident retinal pathology such as retinal vascular occlusion, CNV due to age-related macular degeneration, angioid streaks, trauma, and choroiditis were excluded from the study.
• • 3. patients who received other lines of treatment for DME, such as laser photocoagulation, intravitreal injection of steroids
• • 4. patients known to be glaucomatous or have an IOP ≥20 mmHg were also excluded.
• • -